Jul. 16 at 12:17 AM
The psychedelic sector is back in focus.
I’ve been following this theme long before it became popular, and the volatility has created both huge opportunities and equally large risks.
Names to watch:
$ATAI
$CMPS
$GHRS
$HELP
$DFTX
With renewed interest in next-generation mental health treatments and growing attention from large pharmaceutical companies, sentiment toward the sector could continue improving.
That said, these remain high-risk, high-reward biotech names. Clinical trial results, regulatory milestones, and potential partnerships or acquisitions will likely be the biggest catalysts.
In biotech, conviction must always be paired with disciplined risk management.
Follow me for daily biotech, AI, and high-growth market analysis.
